Search results
Author(s):
Jiaqian Xu
,
Michael D Shapiro
Added:
3 years ago
Author(s):
Shane Prejean
,
Todd M Brown
Added:
3 years ago
Proprotein convertases are proteolytic enzymes that activate proteins by post-translational alterations in protein structure. Proprotein convertase subtilisin/kexin 9 (PCSK9) is a proprotein convertase that binds and inactivates the low-density lipoprotein (LDL) receptor on the surface of hepatocytes resulting in higher levels of serum LDL cholesterol (LDL-C).1 Over-expression of PCSK9 leads to a…
View more
Added:
3 years ago
Dr R Scott Wright (Mayo Clinic, Rochester, MN, US) summarises a pooled analyses of phase 3 studies showing how Inclisiran potently and durably reduces Ldl-c.
Questions:
1. What prompted the study?
2. How does Inclisiran work?
3. What is the study design?
4. Who were the patients?
5. What were the efficacy results?
6. What were the safety findings?
7. What are the implications of this…
View more
Author(s):
Evan A Stein
Added:
3 years ago
Proprotein convertase subtilisin/kexin type 9 (PCSK9), discovered in 2003, is a circulating protein produced predominantly in the liver that plays a significant role in the recycling of LDL receptors (LDLRs).1,2 The LDLR, which normally recycles about 100 times in its lifetime, is the primary pathway for LDL-cholesterol (LDL-C) clearance from circulation. Plasma PCSK9 binds to LDLRs along with…
View more
Author(s):
James Hamilton
Added:
4 years ago
Dr James Hamilton (Vice President Clinical Development at Arrowhead Pharmaceuticals) discusses RNA Interference Targeting Apolipoprotein C-III (APOC3) Results in Deep and Prolonged Reductions in Plasma Triglycerides at AHA 2019.
Filmed on site at AHA 2019 by Radcliffe Cardiology.
Videography: Tom Green
View more
Author(s):
Steven E Nissen
,
Maryam Barkhordarian
Added:
4 months ago
AHA 2023 — Investigator, Dr Steven E Nissen (Cleveland Clinic, US) is interviewed by CardioNerds Medical Education Fellow, Dr Maryam Barkhordarian (HMH Palisades Medical Center, US) on the trial that assessed the efficacy and safety of lepodisiran, a small interfering RNA (NCT05565742).The main purpose of this phase 2, randomised, double-blind, placebo-controlled study (Eli Lilly and Company) is…
View more
Author(s):
Gurleen Kaur
,
Michelle O'Donoghue
Added:
1 year ago
AHA 22 - Dr Gurleen Kaur (Brigham and Women's Hospital, US) joins us in this collaboration between @CardioNerds and Radcliffe Cardiology to interview OCEAN(a)'s primary investigator, DrMichelle O'Donoghue (Brigham and Women's Hospital, US) on the late-breaking data revealed at AHA.
OCEAN(a) was a dose-finding study that aimed to evaluate an siRNA, olpasiran's (Amgen) effect administered…
View more
Author(s):
Steven E Nissen
Added:
1 year ago
In this short summary interview, Dr Steven E Nissen (Cleveland Clinic, Cleveland, US) talks about detailed results from the APOLLO study (NCT01960348).
This placebo-controlled double-blind dose-ranging trial investigated the safety and tolerability of SLN360 (Silence Therapeutics plc) in patients with elevated lipoprotein(a).
Discussion Points:
Trial Rationale
Mechanism of Action
Study…
View more
Author(s):
Mandeep Mehra
,
Christian Inchaustegui
Added:
4 months ago
In 2023, we are excited to partner with @CardioNerds, a dynamic team dedicated to democratizing cardiovascular education. Experience a fresh perspective on the new data through an interview series featuring principal investigators and ambassadors from the CardioNerds family.These interviews are supported by an educational grant from Novo Nordisk Inc. This content is not intended for UK HCPs.
View more
Author(s):
Marianna Fontana
Added:
10 months ago
ESC-HFA 23 — We are joined by Prof Marianna Fontana (University College London, UK), as she outlines the key findings from the phase 3 APOLLO-B study (Alnylam Pharmaceuticals) (NCT03997383).
APOLLO-B investigated the use of patisiran, a transthyretin-directed small interfering RNA, in a cohort of patients with cardiac amyloidosis. 360 patients were enrolled in the trial and were randomized 1:1…
View more